Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: Identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia

Endocrine Practice

Volumn 14, Issue 9, 2008, Pages 1108-1114

  Habra, Mouhammed Amir ^a   Jimenez, Camilo ^a   Huang, Su Chen Eileen ^a   Cote, Gilbert J ^a   Murphy Jr , William A ^a   Gagel, Robert F ^a   Hoff, Ana O ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Fleury   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; KERATINOCYTE GROWTH FACTOR; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; PHOSPHATE; SECRETED FRIZZLED RELATED PROTEIN 4; FGF7 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; GLYCOPROTEIN; MEPE PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHOPROTEIN; SCLEROPROTEIN; SFRP4 PROTEIN, HUMAN;

AGED; ARTICLE; CANCER SURGERY; CASE REPORT; CELL LINE; CONTROLLED STUDY; FEMUR NECK; FOLLOW UP; HEMANGIOPERICYTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ONCOGENIC OSTEOMALACIA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BONE TUMOR; CASE CONTROL STUDY; CELL CULTURE; GENE EXPRESSION PROFILING; GENETICS; HELA CELL; METABOLISM; OSTEOMALACIA; PHYSIOLOGY;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CASE-CONTROL STUDIES; CELLS, CULTURED; EXTRACELLULAR MATRIX PROTEINS; FIBROBLAST GROWTH FACTOR 7; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION PROFILING; GLYCOPROTEINS; HELA CELLS; HEMANGIOPERICYTOMA; HUMANS; MALE; OSTEOMALACIA; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS;

EID: 64049101985     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.9.1108     Document Type: Article

References (33)

1. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1-30.
2. Takeuchi Y, Suzuki H, Ogura S, et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab. 2004;89:3979-3982.
3. Jan de Beur SM, Streeten EA, Civelek AC, et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet. 2002;359:761-763.
4. Cai Q, Hodgson SF, Kao PC, et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med. 1994;330:1645-1649.
5. Kumar R. Tumor-induced osteomalacia and the regulation of phosphate homeostasis. Bone. 2000;27:333-338.
6. White KE, Larsson TE, Econs MJ. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev. 2006;27:221-241.
7. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: regulation by phosphate? Bone. 2004;35:1192-1199.
8. Argiro L, Desbarats M, Glorieux FH, Ecarot B. MEPE, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics. 2001;74:342-351.
9. Carpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab. 2005;90:1012-1020.
10. Sommer S, Berndt T, Craig T, Kumar R. The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J Steroid Biochem Mol Biol. 2007;103:497-503.
11. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000;277:494-498.
12. White KE, Jonsson KB, Carn G, et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001;86:497-500.
13. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007;293:F1577-F1583.
14. Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-Klotho axis in renal regulation of phosphate homeostasis. J Endocrinol. 2007;194:1-10.
15. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770-774.
16. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272-2279.
17. Imel EA, Peacock M, Pitukcheewanont P, et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2006;91:2055-2061.
18. Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112:683-692.
19. Hoffman WH, Jueppner HW, Deyoung BR, O'Dorisio MS, Given KS. Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome. Am J Med Genet A. 2005;134:233-236.
20. Baum M, Schiavi S, Dwarakanath V, Quigley R. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int. 2005;68:1148-1153.
21. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98:6500-6505.
22. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429-435.
23. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561-568.
24. Rowe PS, de Zoysa PA, Dong R, et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics. 2000;67:54-68.
25. Nampei A, Hashimoto J, Hayashida K, et al. Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J Bone Miner Metab. 2004;22:176-184.
26. Gowen LC, Petersen DN, Mansolf AL, et al. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem. 2003;278:1998-2007.
27. Liu S, Brown TA, Zhou J, et al. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol. 2005;16:1645-1653.
28. Dobbie H, Unwin RJ, Faria NJ, Shirley DG. Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption. Nephrol Dial Transplant. 2008;23:730-733.
29. Rubin JS, Bottaro DP, Chedid M, et al. Keratinocyte growth factor. Cell Biol Int. 1995;19:399-411.
30. Erdag G, Medalie DA, Rakhorst H, Krueger GG, Morgan JR. FGF-7 expression enhances the performance of bioengineered skin. Mol Ther. 2004;10:76-85.
31. Miller JR. The Wnts. Genome Biol. 2002;3:REVIEWS3001.
32. Berndt TJ, Bielesz B, Craig TA, et al. Secreted frizzled-related protein-4 reduces sodium-phosphate co-transporter abundance and activity in proximal tubule cells. Pflugers Arch. 2006;451:579-587.
33. Berndt T, Craig TA, Bowe AE, et al. Secreted frizzledrelated protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest. 2003;112:785-794.